Jeito Capital | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Jeito Capital/Activity

Jeito Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Odyssey Therapeutics priced an upsized $304M IPO and began trading on Nasdaq under ODTX.

Odyssey Therapeutics

Odyssey Therapeutics Jeito Capital

globenewswire.comMAY 8, 2026

MAY 8, 2026

Team Change

Appointed Elaine Caughey as Partner, Business Development and Investor Relations, and Sarah Shackelton as Partner, Talent.

Elaine Caughey and Sarah Shackelton join as Partners

businesswire.comMAY 5, 2026

MAY 5, 2026

New Fund

Closed Jeito II Fund at over EUR 1 billion (~$1.2B), the largest-ever raise by a fully independent European biopharma-focused fund, tripling AUM to EUR 1.6B.

Jeito II Fund

jeito.lifeAPR 8, 2026

biopharmadive.com

fiercebiotech.com

APR 8, 2026

Investment

Cornerstone investor in the oversubscribed $197M Series A second closing for Alveus Therapeutics (obesity and metabolic disease).

Alveus Therapeutics

Alveus Therapeutics Jeito Capital

biospace.comFEB 24, 2026

FEB 24, 2026

Team Change

Promoted Ksenija Pavletic to General Partner and Chief Commercial Officer.

Ksenija Pavletic promoted to General Partner

finance.yahoo.comOCT 2025

OCT 2025

Team Change

Promoted Mehdi Ainouche to Partner and Julien Elric to Senior Principal.

Mehdi Ainouche promoted to Partner; Julien Elric to Senior Principal

globenewswire.comMAY 12, 2025

MAY 12, 2025

3 exits· JAN 2023 – JUL 2024Show all

Exit

Portfolio company HI-Bio (Human Immunology Biosciences) acquired by Biogen (~$1.15B upfront, up to $650M in milestones).

HI-Bio

HI-Bio Jeito Capital

investors.biogen.comJUL 2, 2024

JUL 2, 2024

Exit

Portfolio company EyeBio acquired by Merck & Co. ($1.3B upfront, up to $1.7B in milestones).

EyeBio

EyeBio Jeito Capital

merck.comJUL 2024

biopharminternational.com

JUL 2024

Exit

Portfolio company Neogene Therapeutics acquired by AstraZeneca (initial $200M plus up to $120M in milestones).

Neogene Therapeutics

Neogene Therapeutics Jeito Capital

astrazeneca.comJAN 16, 2023

JAN 16, 2023